The Ministry of Health approved a domestic innovative drug for the treatment of diseases of the central nervous system
Avineiro company of the ChemRar Group announces that it has received a registration certificate from the Russian Ministry of Health for the drug AVIANDR® for the treatment of anxiety disorders. The drug was developed with the support of the Russian Ministry of Industry and Trade and within the framework of the NTI Neuronet roadmap. The full cycle of development, starting with the synthesis of the molecule, clinical trials and production of the drug was carried out on the territory of the Russian Federation.
AVIANDR® has multitarget activity, acting on serotonin, adrenergic and dopamine receptors, which determines the presence of anti-anxiety and antidepressant properties in the drug.
During clinical studies, the effectiveness of the drug was demonstrated. Physician researchers have observed its antidepressant effect and consider it possible to recommend AVIANDR® for the treatment of generalized anxiety disorder and anxiety that occurs, including as a consequence of the new coronavirus infection (COVID-19).
The results of multicenter randomized placebo-controlled studies showed a rapid reduction in anxiety symptoms — already from the first week of taking the drug, while patients did not experience drowsiness and other side effects characteristic of traditional therapy, which is important for patient compliance with the prescribed regimen (adherence to therapy). Anxiety states are often accompanied by increased heart rate, high fatigue, weakness, increased blood pressure, sweating, and abdominal pain; the drug AVIANDR® reduced the manifestation of such symptoms.
Priezzheva Ekaterina Gennadievna, Deputy Minister of Industry and Trade of the Russian Federation: “One of the priorities of the Ministry of Industry and Trade of Russia is to achieve technological sovereignty in the pharmaceutical industry. The creation of modern, including innovative, medicines with our own development lines is a stage of development and a priority of technology policy in the approved Concept of Technological Development of the Russian Federation for the period until 2030. The development of AVIANDR® is an example of this approach. It should be noted that the innovative molecule was created by scientists using government support mechanisms provided for by the PharmaMed state program . The Ministry of Industry and Trade of Russia will continue to create and develop existing state support measures aimed at bringing science, technology and subjects of drug circulation closer together, including within the framework of the Development Strategy of the pharmaceutical industry for the period until 2030.”
Chairman of the Board of Directors of the ChemRar Group Andrey Ivashchenko: “This is an innovative drug for the treatment of anxiety disorders with a full cycle of development and production in Russia, which at the same time is a world-class innovation and a discovery of our scientists. When using the drug AVIANDR®, no dependence was observed and no cases of withdrawal syndrome were observed upon completion of treatment. The drug did not cause adverse reactions from the endocrine system, such as weight gain and sexual dysfunction, typical of other psychotropic drugs. According to the data we received during the research, the potential of the drug is promising. We continue research in other nosologies, such as depression, panic attacks and Alzheimer’s disease.»
The ChemRar Group (www.chemrar.ru) unites research and production organizations in the field of development of innovative medicines, diagnostics, prevention and new methods of treating life-threatening diseases in Russia and abroad.
More news in our Telegram channel https://t.me/chemrarpharma
***
For more information, please contact:
Press service of the ChemRar Group
Tel. +7 (495) 925 30 74 , welcome@chemrar.ru